Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Stok Raporu

Piyasa değeri: US$682.8m

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Arcturus Therapeutics Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Arcturus Therapeutics Holdings şirketinin toplam hissedar öz sermayesi $258.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $388.6M ve $130.0M dir.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$260.33m
EşitlikUS$258.58m
Toplam yükümlülüklerUS$130.03m
Toplam varlıklarUS$388.61m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 09

Arcturus: A Hidden Gem In The Biotech Sector

Jun 08

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

May 11
These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ARCT 'nin kısa vadeli varlıkları ( $347.0M ) kısa vadeli yükümlülüklerini ( $91.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: ARCT şirketinin kısa vadeli varlıkları ( $347.0M ) uzun vadeli yükümlülüklerini ( $38.3M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ARCT borçsuzdur.

Borcun Azaltılması: ARCT şirketinin 5 yıl önce borç/öz sermaye oranı 46.2% iken borcu yok.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ARCT şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: ARCT serbest nakit akışı her yıl % { 3.6 1.4 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.


Sağlıklı şirketleri keşfedin